Provided by HIVandHepatitis.com
Details Category: HBV Treatment Published on Tuesday, 08 April 2014 00:00 Written by HIVandHepatitis.com
The European Association for the Study of the Liver's International Liver Congress (EASL 2014) takes place April 9-13 at the ExCel Centre in London. The annual conference is one of the key annual scientific meetings covering viral hepatitis and its complications. Also on Thursday, the World Health Organization (WHO) will release new global guidelines for hepatitis C.
With next-generation direct-acting antivirals exiting the development pipeline or in the final stages of testing, new treatments for hepatitis C will be a key theme of the meeting, in particular long-awaited interferon-free regimens. New data will be presented on several approved or Phase 3 drugs -- many with cure rates in the 90% to 100% range -- including:
- Gilead Sciences' sofosbuvir (Sovaldi) plus ledipasvir coformulation used alone or with ribavirin or a third DAA.
- Janssen's protease inhibitor simeprevir (Olysio) in interferon-free regimens.
- AbbVie's "3D" combination containing ABT-450, ABT-333, and ABT-267.
- Bristol-Myers Squibb's daclatasvir and asunaprevir.
- Merck's MK-5172 and MK-8742.
- Boehringer Ingelheim's faldaprevir.
Continue reading full article here
No comments:
Post a Comment